Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis

Journal of Psychopharmacology

Volumn 24, Issue 10, 2010, Pages 1515-1524

  Daumann, J ^a   Wagner, D ^a   Heekeren, K ^a   Neukirch, A ^a   Thiel, C M ^b   Gouzoulis Mayfrank, E ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

alertness; dimethyltryptamine; experimental psychosis; ketamine; pharmacological fMRI

Indexed keywords

KETAMINE; N,N DIMETHYLTRYPTAMINE; PLACEBO;

ADULT; ALERTNESS; AMYGDALOID NUCLEUS; ARTICLE; BLOOD OXYGENATION; CLAUSTRUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HUMAN EXPERIMENT; INSULA; MALE; MENTAL PERFORMANCE; NORMAL HUMAN; PARIETAL LOBE; POTENTIAL DIFFERENCE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; STIMULUS RESPONSE; SYSTEMATIC REVIEW; TEMPORAL LOBE; THALAMUS;

ADULT; ATTENTION; AUDITORY PERCEPTION; BRAIN; CROSS-OVER STUDIES; CUES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KETAMINE; MAGNETIC RESONANCE IMAGING; MALE; N,N-DIMETHYLTRYPTAMINE; NEURONS; ORGAN SPECIFICITY; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN 5-HT2 RECEPTOR AGONISTS; TASK PERFORMANCE AND ANALYSIS; VISUAL PERCEPTION;

EID: 77958003320     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109103227     Document Type: Article

References (70)

1. Abel, KM, Allin, MP, Kucharska-Pietura, K., Andrew, C., Williams, S., David, AS, et al. (2003) Ketamine and fMRI BOLD signal: distinguishing between effects mediated by change in cognitive state. Hum Brain Mapp 18: 135-145.
2. Abi-Saab, WM, D'Souza, DC, Moghaddam, B., Krystal, JH (1998) The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 31: 104-109.
3. Addington, J., Addington, D. (1998) Visual attention and symptoms in schizophrenia: a 1-year follow-up. Schizophr Res 34: 95-99.
4. American Psychiatric Association (APA) (1994) DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. Washington DC.
5. Andreasen, NC (1983) The Scale for the Assessment of Negative Symptoms (SANS). The University of Iowa ; Iowa City, IA.
6. Andreasen, NC (1984) The Scale for the Assessment of Positive Symptoms (SAPS). The University of Iowa ; Iowa City, IA.
7. Andreasen, NC, Rezai, K., Alliger, R., Swayze, VW, Flaum, M., Kirchner, P., et al. (1992) Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with Xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49: 943-952.
8. Berlucchi, G. (2006) Inhibition of return: A phenomenon in search of a mechanism and a better name. Cogn Neuropsychol 23: 1065-1074.
9. Buchsbaum, MS, Nuechterlein, KH, Haier, RJ, Wu, J., Sicotte, N., Hazlett, E., et al. (1990) Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by positron emission tomography. Br J Psychiatry 156: 216-227.
10. Burdett, NG, Menon, DK, Carpenter, TA, Jones, JG, Hall, LD (1995) Visualisation of changes in regional cerebral blood flow (rCBF) produced by ketamine using long TE gradient-echo sequences: preliminary results. Magn Reson Imaging 13: 549-553.
11. Carpenter, WT (1999) The schizophrenia ketamine challenge study debate. Biol Psychiatry 46: 1081-1091.
12. Carter, OL, Burr, DC, Pettigrew, JD, Wallis, GM, Hasler, F., Vollenweider, FX (2005) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci 17: 1497-1508.
13. Cleghorn, JM, Franco, S., Szechtman, B., Kaplan, RD, Szechtman, H., Brown, GM, et al. (1992) Towards a brain map of auditory hallucinations. Am J Psychiatry 149: 1062-1069.
14. Cohen, RM, Semple, WE, Gross, M., Nordahl, TE, DeLisi, LE, Holcomb, HH, et al. (1987) Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sci 40: 2031-2039.
15. Corbetta, M., Shulman, GL (2002) Control of goal-directed and stimulus-driven attention in the brain. Nat Neurosci 3: 201-215.
16. Cornblatt, BA, Malhotra, AK (2001) Impaired attention as an endophenotype for molecular genetic studies of schizophrenia. Am J Med Genet 105: 11-15.
17. Coull, JT, Nobre, AC, Frith, CD (2001) The noradrenergic alpha2 agonist clonidine modulates behavioural and neuroanatomical correlates of human attentional orienting and alerting. Cereb Cortex 11: 73-84.
18. Curtis, VA, Bullmore, ET, Morris, RG, Brammer, MJ, Williams, SCR, Simmons, A., et al. (1999) Attenuated frontal activation in schizophrenia may be task dependent. Schizophr Res 37: 35-44.
19. Daumann, J., Heekeren, K., Neukirch, A., Thiel, CM, Möller-Hartmann, W., Gouzoulis-Mayfrank, E. (2008) Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology 200: 573-583.
20. Dittrich, A., von Arx, S., Staub, S. (1985) International study on altered states of consciousness (ISASC). Summary of the results. German J Psychol 9: 319-339.
21. D'Souza, DC, Berman, RM, Krystal, JH, Charney, DS (1999) Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biol Psychiatry 46: 1060-1080.
22. Dye, SM, Spence, SA, Bench, CJ, Hirsch, SR, Stefan, MD, Sharma, T., et al. (1999) No evidence for left superior temporal dysfunction in asymptomatic schizophrenia and bipolar disorder. PET study of verbal fluency. Br J Psychiatry 175: 367-374.
23. Ebmeier, KP, Blackwood, DH, Murray, C., Ebmeier, KP, Blackwood, DH, Murray, C., et al. (1993) Single-photon emission computed tomography with 99mTc-exametazime in unmedicated schizophrenic patients. Biol Psychiatry 33: 487-495.
24. Fan, J., McCandliss, BD, Sommer, T., Raz, A., Posner, MI (2002) Testing the efficiency and independence of attentional networks. J Cogn Neurosci 14: 340-347.
25. Fink, GR, Marshall, JC, Shah, NJ, Weiss, PH, Halligan, PW, Grosse-Ruyken, M., et al. (2000) Line bisection judgments implicate right parietal cortex and cerebellum as assessed by fMRI. Neurology 54: 1324-1331.
26. Fletcher, PC, Frith, CD, Grasby, PM, Friston, KJ, Dolan, RJ (1996) Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia. J Neurosci 16: 7055-7062.
27. Frith, CD, Friston, KJ, Herold, S., Silbersweig, D., Fletcher, P., Cahill, C., et al. (1995) Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Br J Psychiatry 167: 343-349.
28. Fu, CHY, Abel, KM, Allin, MPG, Gasston, D., Costafreda, SG, Suckling, J., et al. (2005) Effects of ketamine on prefrontal and striatal regions in an overt verbal fluency task: a functional magnetic resonance study. Psychopharmacology 183: 92-102. (Pubitemid 41484186)
29. Fu, CHY, McGuire, PK (1999) Functional neuroimaging in psychiatry. Philos Trans R Soc Lond B Biol Sci 354: 1359-1370.
30. Giessing, C., Thiel, CM, Stephan, KE, Rösler, F., Fink, GF (2004) Visuospatial attention: how to measure effects of infrequent, unattended events in a blocked stimulus design. Neuroimage 23: 1370-1381.
31. Goldberg, TE, Gold, JM (1995) Neurocognitive functioning in patients with schizophrenia. In: Bloom, FE, Kupfer, DJ, (eds). Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, pp. 1245-1257.
32. Gouzoulis-Mayfrank, E., Heekeren, K., Timmerbeil, A., Stoll, M., Stock, C., Obradovic, M., et al. (2005) Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT). a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38: 301-311.
33. Gouzoulis-Mayfrank, E., Hermle, L., Thelen, B., Sass, H. (1998) History, rationale and potential of experimental hallucinogenic drug research in psychiatry. Pharmacopsychiatry 31: 63-68.
34. Gouzoulis-Mayfrank, E., Schreckenberger, M., Sabri, O., Arning, C., Thelen, B., Spitzer, M., et al. (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 20: 565-581.
35. Gouzoulis-Mayfrank, E., Thelen, B., Maier, S., Heekeren, K., Kovar, A., Sass, H., et al. (2002) Effects of the Hallucinogen Psilocybin on Covert Orienting of Visual Attention in Humans. Neuropsychobiology 45: 205-212.
36. Grunwald, T., Beck, H., Lehnertz, K., Blümcke, I., Pezer, N., Kurthen, M., et al. (1999) Evidence relating human verbal memory to hippocampal N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A 96: 12085-12089.
37. Honey, GD, Honey, RAE, Sharar, SR, Turner, DC, Pomarol-Clotet, E., Kumaran, D., et al. (2005) Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of subsequent retrieval task. Psychopharmacology 181: 445-457.
38. Honey, RAE, Honey, GD, O'Loughlin, C., Sharar, SR, Kumaran, D., Bullmore, ET, et al. (2004) Acute ketamine administration alters the brain responses to executive demands in verbal working memory task: an fMRI study. Neuropsychopharmacology 29: 1203-1214.
39. Javitt, DC, Zukin, SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
40. Kapur, S., Seeman, P. (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors - implications for models of schizophrenia. Mol Psychiatry 7: 837-844.
41. Krystal, JH, Karper, LP, Seibyl, JP, Freeman, GK, Delaney, R., Bremner, JD, et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
42. Lahti, AC, Holcomb, HH, Medoff, DR, Tamminga, CA (1995) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6: 869-872.
43. Manoach, DS, Press, DZ, Thangaraj, V., Searl, MM, Goff, DC, Halpern, E., et al. (1999) Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biol Psychiatry 45: 1128-1137.
44. McGuire, PK, Shah, GMS, Murray, RM (1993) Increased blood flow in Broca's area during auditory hallucinations in schizophrenia. Lancet 342: 703-706.
45. Michie, PT, Kent, A., Stienstra, R., Castine, R., Johnston, J., Dedman, K., et al. (2000) Phenotypic markers as risk factors in schizophrenia: neurocognitive functions. Aust N Z J Psychiatry 34: 74-85.
46. Moghaddam, B., Adams, B., Verma, A., Daly, D. (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
47. Mueser, KT, Bellack, AS, Brady, EU (1990) Hallucinations in schizophrenia. Acta Psychiatr Scand 82: 26-29.
48. Nichols, DE (2004) Hallucinogens. Pharmacol Ther 101: 131-181.
49. Northoff, G., Richter, A., Bermpohl, F., Grimm, S., Martin, E., Marcar, VL, et al. (2005) NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI. Schizophr Res 72: 235-248.
50. Overall, JE, Gorham, DR (1962) The brief psychiatric rating scale. Psychol Rep 10: 799-812.
51. Palmer, BW, Heaton, RK, Paulsen, JS, Kuck, J., Braff, D., Harris, MJ, et al. (1997) Is it possible to be schizophrenic yet neuropsychologically normal ? Neuropsychology 11: 437-446.
52. Posner, MI, Petersen, SE (1990) The attention system of the human brain. Annu Rev Neurosci 13: 182-196.
53. Robertson, IH, Mattingley, JB, Rorden, C., Driver, J. (1998) Phasic alerting of neglect patients overcomes their spatial deficit in visual awareness. Nature 395: 169-172.
54. Rubinsztein, JS, Rogers, RD, Riedel, WJ, Mehta, MA, Robbins, TW, Sahakian, BJ (2001) Acute dietary tryptophan depletion impairs maintenance of "affective set" and delayed visual recognition in healthy volunteers. Psychopharmacology 154: 319-326.
55. Schultze-Lutter, F., Addington, J., Ruhrmann, S., Klosterkoetter, J. (2007) Schizophrenia Proneness Instrument, Adult version (SPI-A). Giovanni Fioriti Editore s.r.l, Rome, Italy.
56. Shergill, SS, Brammer, MJ, Williams, SC, Murray, RM, McGuire, PK (2000) Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch Gen Psychiatry 57: 1033-1088.
57. Snyder, SH (1988) Psychotogenic drugs as models for schizophrenia. Neuropsychopharmacology 1: 197-199.
58. Spence, SA, Liddle, PF, Stefan, MD, Hellewell, JS, Sharma, T., Friston, KJ, et al. (2000) Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk. Br J Psychiatry 176: 52-60.
59. Stevens, A., Goldman-Rakic, PS, Gore, JC, Fulbright, RK, Wexler, BE (1998) Cortical dysfunction in schizophrenia during auditory word and tone working memory demonstrated by functional magnetic resonance imaging. Arch Gen Psychiatry 55: 1097-1103.
60. Strassman, RJ, Qualls, CR, Uhlenhuth, EH, Kellner, R. (1994) Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51: 98-108.
61. Sturm, W., Willmes, K. (2001) On the functional neuroanatomy of intrinsic and phasic alertness. Neuroimage 14: 76-84.
62. Talairach, J., Tournoux, P. (1988) Co-planar Stereotactic Atlas of the Human Brain. Thieme, Stuttgart.
63. Thiel, C., Fink, G. (2007) Visual and auditory alertness: modality-specific and supramodal neural mechanisms and their modulation by nicotine. J Neurophysiol 97: 2758-2768.
64. Van Zomeren, AH, Brouwer, WH, (eds) (1994) Clinical Neuropsychology of Attention. New York: Oxford Univ. Press.
65. Volkow, ND, Brodie, JD, Wolf, AP, Angrist, B., Russell, J., Cancro, R. (1986) Brain metabolism in patients with schizophrenia before and after acute neuroleptics administration. J Neurol Neurosurg Psychiatry 49: 1199-1202.
66. Vollenweider, FX, Vollenweider-Scherpenhuyzen, MF, Babler, A., Vogel, H., Hell, D. (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897-3902.
67. Vollenweider, FX, Vontobel, P., Oye, I., Hell, D., Leenders, KL (2000) Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34: 35-43.
68. Weinberger, DR, Berman, KF, Illowsky, BP (1988) Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 45: 609-615.
69. Witte, EA, Davidson, MC, Marrocco, RT (1997) Effects of altering brain cholinergic activity on covert orienting of attention: comparison of monkey and human performance. Psychopharmacology 132: 324-334.
70. Zahn, TP, Rosenthal, D., Shakow, D. (1963) Effects of irregular preparatory intervals on reaction time in schizophrenia. J Abnorm Soc Psychol 67: 44-52.